Psychiatric Disorders, Skin Restricted Lupus
Conditions
Keywords
Skin restricted lupus, Psychiatric disorders, Inflammation, Kynurenine pathway
Brief summary
The purpose of this study is to determine the role of inflammation in the high prevalence of psychiatric disorders in skin-restricted lupus (SRL) patients. SRL is an inflammatory disease. Inflammation can lead to a decrease in the synthesis of neurotransmitters via the activation of the IDO enzyme and to induce the synthesis of neurotoxic molecules (kynurenin pathway). This leads to the development of psychiatric disorders. Investigator therefore want to compare inflammation and neurotransmitter synthesis in SRL patients according to the presence or absence of psychiatric disorders. Investigator expect a decrease in neurotransmitter synthesis and activation of the kynurenin pathway in patients with a psychiatric disorder.
Detailed description
The purpose of this study is to determine the role of inflammation in the high prevalence of psychiatric disorders in skin-restricted lupus (SRL) patients. SRL is an inflammatory disease. Inflammation can lead to a decrease in the synthesis of neurotransmitters via the activation of the IDO enzyme and to induce the synthesis of neurotoxic molecules (kynurenin pathway). This leads to the development of psychiatric disorders. Investigator therefore want to compare inflammation and neurotransmitter synthesis in SRL patients according to the presence or absence of psychiatric disorders. Investigator expect a decrease in neurotransmitter synthesis and activation of the kynurenin pathway in patients with a psychiatric disorder.
Interventions
BIOLOGICALBiological dosage from plasma
The purpose of this study is to determine the role of inflammation in the high prevalence of psychiatric disorders in skin-restricted lupus (SRL) patients. SRL is an inflammatory disease. Inflammation can lead to a decrease in the synthesis of neurotransmitters via the activation of the IDO enzyme and to induce the synthesis of neurotoxic molecules (kynurenin pathway). This leads to the development of psychiatric disorders.
Sponsors
Société Française de Cardiologie
University Hospital, Clermont-Ferrand
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of cutaneous lupus: Chronic (or discoid) cutaneous lupus during activity: Either the typical chronic lupus plaque (associated with erythema, hyperkeratosis, atrophy) sitting on the photoexposed areas of the face and / or on the scalp; The erythematous forms in sheets are excluded in order not to include patients who may be ambiguous in diagnosis with systemic lupus. Either form tumidus of chronic lupus. Typical cutaneous histology of chronic cutaneous lupus (orthokeratosis hyperkeratosis with horny plugs, thickening of the basal membrane area (PAS staining), lymphocytic infiltrate predominantly peri-necular but possibly having lichenoid aspects with vacuolation of the epidermal basal layer and cytoids). sub-acute erythematous form in the course of evolution, thus defined Lesions distributed on the body's photoexposed areas, erythematous, squamous leaving scarred scars, the intensity of which is clearly aggravated by exposure to light. Diagnostic histology compatible with diagnosis (hyperketatose orthokeratosique, middle and / or higher dermal lymphocytic infiltrate). Presence of anti-Ro serum antibodies. \- Age greater than or equal to 18 years
Exclusion criteria
* Uncertain diagnosis of lupus * Systemic lupus * Presence of anti-native DNA antibodies at a rate\> 1/80 * Proteinuria greater than 0.5g / 24h (or more than 3+), * Presence of more than 3 American College of Rheumatology (ACR) criteria for the diagnosis of systemic lupus * Other inflammatory dermatological pathology * Chronic inflammatory disease (other than lupus) * Diabetes * Surgery in the previous month * Immunosuppressive therapy * Pregnant and lactating women * Abuse or dependence on all poisons (except tobacco and alcohol) * Mental retardation * Illiteracy or not sufficiently fluent in French * Patients under legal protection Patients with acute inflammatory (and / or infectious, and / or traumatic) illness or who have taken an anti-inflammatory (other than for cutaneous lupus), analgesic, antihistamine or aspirin therapy within 15 days prior to inclusion Participate in the study, but will be offered to shift the inclusion. They may be included 15 days after an inflammatory disease or discontinuation of such treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Difference in IDO activation and neurotransmitters synthesis inhibition between SRL patients with and without psychiatric disorders. | Blood samples at day 1 and plasma analyses at the end of the study (when all patients will be included, up to 15 months) | comparison of plasma: * kynurenine / tryptophan and 3-hydroxykynurenine / kynurenine ratios for IDO activation * serotonin / tryptophan) et tyrosine / phenylalanine ratios for neurotransmitters synthesis inhibition between SRL patients with and without psychiatric disorders. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Difference in kynurenine pathway activation between SRL patients with and without psychiatric disorders. | Blood samples at day 1 and plasma analyses at the end of the study (when all patients will be included, up to 15 months) | comparison of plasma kynurenic acid / kynurenine and quinolinic acid / kynurenine ratios between SRL patients with and without psychiatric disorders. |
| Difference in cytokine concentration between SRL patients with and without psychiatric disorders | Blood samples at day 1 and plasma analyses at the end of the study (when all patients will be included, up to 15 months) | comparison of plasma TNFα, IFNα, IFNγ, IL1, IL1ᵦ, IL2, IL6, IL4, IL8, IL10, IL17, IL18 and CRP between SRL patients with and without psychiatric disorders. |
Countries
France
Outcome results
None listed